1 Title

2 Towards a Buruli Ulcer Rapid Diagnostic Test that Targets Mycolactone

3

4 Authors

<u>...</u>

1

5	warina	i Siirin," Bijan Pedram," Maria J. Gonzalez-Moa," Louisa Warryn,"" Rie Yotsu, " Jean M. Saunders,"	
6	Aaron	E. Saunders, ⁶ Richard K. Baldwin, ⁶ Jessica L. Porter, ⁷ Timothy P. Stinear, ⁷ Israel Cruz-Mata, ^{8,9}	
7	Dziedzom Komi de Souza, ^{8,10} Gerd Pluschke, ^{2,3} Marco A. Biamonte ¹		
8			
9	1.	Drugs & Diagnostics for Tropical Diseases, San Diego, California, United States of America	
10	2.	Swiss Tropical and Public Health Institute, Allschwil, Switzerland.	
11	3.	University of Basel, Basel, Switzerland.	

45.

. .

- 12 4. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
- 13 5. Department of Tropical Medicine, Tulane School of Public Health and Tropical Medicine, New
- 14 Orleans, Louisiana, United States of America
- 15 6. NanoComposix, a Fortis Life company, San Diego, California, United States of America
- 16 7. Department of Microbiology and Immunology, Doherty Institute, University of Melbourne,
- 17 Victoria, Australia
- 18 8. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
- 19 9. National School of Public Health, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- 20 10. Noguchi Memorial Institute, Accra, Ghana.

21 Abstract

22 We report the development of a prototype rapid diagnostic test for Buruli ulcer, an ulcerative necrotizing 23 skin disease caused by *M. ulcerans*. The test was designed to detect mycolactone, a metabolite unique to 24 *M. ulcerans*. The chief technical challenge was to develop a simple workflow to extract trace amounts of 25 mycolactone from wound exudates collected with a swab and, after a concentration step, to visualize the 26 mycolactone by means of a lateral flow assay. This was achieved by utilizing a mouse monoclonal antibody 27 specific for mycolactone and magnetic gold nanoshells. The latter are a novel class of reporter particles 28 consisting of a ferrite core, a silica gel middle layer that serves to decrease the overall density of the 29 nanoparticle and facilitate its resuspension in aqueous media, and an outer layer of gold, which provides 30 a dark coloration through plasmon resonance effects. These nanoparticles, once conjugated to the anti-31 mycolactone antibody, enable the immunomagnetic concentration of the targeted analyte and its 32 detection by lateral flow assay. The test procedure can be conducted within 2 hours with a magnetic rack 33 and no powered instrumentation is required. The test can detect as little as 3.5–7 ng of mycolactone 34 collected on a swab.

35 Author summary

36 Buruli ulcer is a neglected tropical disease that affects the poorest of the poorest in Africa. Even young 37 people can harbor large ulcers, with raw flesh directly exposed. While antibiotic treatments exist, there 38 are no simple methods to diagnose the disease. Here, we attempted to detect mycolactone, a small 39 molecule produced by the bacteria that causes Buruli ulcer. One difficulty was the sample type to be used, 40 as the open wounds are sampled with a swab. The question was how to extract mycolactone from the 41 swab and then detect it by means of a rapid diagnostic test, without using sophisticated equipment. We 42 tried to answer this question by combining monoclonal antibodies specific for mycolactone and novel 43 magnetic nanoparticles to concentrate and visualize mycolactone with a rapid test.

44 Introduction

Buruli ulcer (BU) is a progressive necrotizing skin infection caused by Mycobacterium ulcerans. The disease 45 starts as a painless papule which can progress to a nodule and eventually degenerate into a large ulcer 46 47 where the skin no longer covers the underlying tissue [1, 2]. Buruli ulcer has been reported in 34 countries 48 [3], and is mostly found in rural areas of West Africa, though a recrudescence has been noted in Australia 49 [4] where its transmission has been ascribed to possums and other animal reservoirs [5, 6]. In 2019, before 50 the COVID-19 pandemic which affected active case finding campaigns, 2,271 new cases were recorded 51 worldwide, and the incidence rate remained at the same level with 2,121 cases reported in 2022 [7]. The 52 disease is believed to be vastly under-reported partly due to its presence in very remote communities 53 hindering access to care, and also because of the lack of awareness, of reporting system, and of field-54 friendly diagnostic tools [8].

55 Buruli ulcer remains one of the neglected tropical diseases (NTDs) in need of improved diagnostic tests. 56 With oral antibiotic treatment available [9], decentralizing diagnosis would facilitate strategies for early 57 detection, timely treatment, and prevention of permanent disability. However, there are no diagnostics 58 suitable for point-of-care applications. The well-established diagnostics are based on direct M. ulcerans 59 pathogen confirmation by in vitro culture (definitive positive diagnosis), PCR, smear examination for acid-60 fast bacilli, or histopathology. These diagnostics require either a sophisticated laboratory or have low 61 sensitivity. An isothermal amplification technique (LAMP assay) has been proposed as alternative to PCR 62 and, while not commercial, is promising [10, 11]. A method based on thin layer chromatography has also 63 been evaluated and works better with fine needle aspirates from nodules than with swabs from open 64 wounds [12, 13].

65 Given the importance of securing new diagnostic tools for Buruli ulcer and to help guiding the 66 development of new diagnostic tools, the World Health Organization (WHO) in consultation with different

partners developed a preliminary Target Product Profile (TPP) in 2018 [14] which was revisited in 2022 67 68 [15]. The TPP served as the starting point for the efforts described herein. Of particular relevance to this 69 work was the desire stated in the TPP to see a diagnostic test capable of detecting mycolactone. 70 Mycolactone is a unique metabolite of *M. ulcerans* composed of a macrolide core substituted with a fatty-71 acid sidechain (MW = 743.02). Mycolactone has cytotoxic, immunosuppressive, and analgesic effects that 72 induce the large debilitating skin lesions that develop when the infection is not treated [16]. It is further believed that because mycolactone production is related to the viability of the mycobacterium, a 73 74 mycolactone test has the potential to be used not only for diagnosis, but also to assess response to 75 treatment and cure.

Here, we report the development of a prototype rapid test for Buruli ulcer, formatted as a lateral flow assay capable of identifying mycolactone as the disease biomarker. The test was specifically designed to isolate trace amounts of mycolactone from wound exudates, and then analyze the concentrated mycolactone on a lateral flow assay with minimal sample processing.

80

81




Figure 1. Structures of (1) mycolactone A/B isomer mixture , (2) biotinylated analog PG-204 , and (3) acetyl analog
PG-119.

85 Materials and Methods

Assay Principle. We devised a competitive lateral flow assay featuring two innovations. The first was the 86 87 use of a mouse monoclonal antibody specific for mycolactone [17], which has previously shown value in 88 an ELISA [18, 19]. The second innovation was the use of custom-made nanoparticles specifically designed 89 to enable immunomagnetic concentration of the analyte mycolactone while being darkly colored and 90 providing a visual signal when run on a lateral flow test. These nanoparticles, dubbed magnetic gold 91 nanoshells (Mag-GNS) consist of a ferrite center, a silica gel middle layer, and a gold outer shell (Figure 2). 92 The ferrite center allows for magnetic concentration, the silica gel layer encapsulates the ferrite and lowers 93 the overall density of the nanoparticles allowing for their resuspension in aqueous media, and the gold 94 shell surface absorbs light extremely efficiently due to plasmon resonance effects. This quantum physics phenomenon comes into play when metal nanoparticles reach the nm scale, in this case creating a dark 95 96 brown-gray color, nearly black, a surprising hue for a gold particle. The gold shell is further functionalized 97 with carboxylic acid groups for covalent conjugation to a detector antibody, and was custom made by 98 nanoComposix, a Fortis LifeScience Company (San Diego, CA, USA).




99

100Figure 2. Magnetic gold nanoshells. Schematics and transmission electron101microscopy views of the particles being built starting from a ferrite core, which is102then coated with silica gel (greyish), which is in turn studded with gold crystals103(little black dots), used as nucleation points to grow the gold shell.

In parallel, a test strip was developed as shown in **Figure 3**, where a sample pad (glass fiber), nitrocellulose, and an absorbent pad were laminated onto a backing card. The key property of the strip was a test line made of a mixture of biotinylated mycolactone analog PG-204 (**Figure 1**) and polystreptavidin, which effectively immobilized the PG-204 probe at the test line. The strip also included a control line of antimouse antibody to capture magnetic gold nanoshells that migrated past the test line. The strip was placed in a plastic cassette for ease of use and transportation.

110 Combined with the magnetic nanoshells covalently conjugated to an anti-mycolactone antibody, the strip 111 allowed for a competitive assay. If the sample to be analyzed is devoid of mycolactone, then the conjugate 112 binds to PG-204, itself immobilized on the test line, and produces a black test line. Conversely, if the test 113 sample contains significant amounts of mycolactone, the latter saturates the binding sites on the anti-114 mycolactone antibody, and the conjugate is no longer captured by PG-204 at the test line. In summary, the 115 resulting test line intensity is inversely proportional to the concentration of mycolactone in the sample.

116




118

119	Figure 3. Competitive-format test strip schematic. Biotinylated mycolactone is
120	added to poly-streptavidin and the mixture is immobilized at the test line
121	position. A secondary goat anti-mouse antibody is immobilized at the control
122	line position. The magnetic-GNS anti-mycolactone conjugate will bind to the
123	biotinylated mycolactone at the test line. In the presence of mycolactone in the
124	sample, the mycolactone binding sites on the conjugate will become saturated,
125	resulting in a test line intensity that is inversely proportional to the amount of
126	mycolactone in the sample.

127

Assay workflow. We envisioned that the workflow of the finished assay would be as shown in Figure 4, with its components described in the next paragraphs of the Materials and Methods section. The magnetic nanoshells, after being conjugated to anti-mycolactone antibody (the "conjugate"), would be lyophilized for storage and transportation, and reconstituted in the laboratory or at the point of care. Next, a swab

containing a wound exudate would be transferred to a tube containing extraction buffer (step 1). The reconstituted magnetic nanoparticles would be added (step 2), incubated with the extracted sample to capture the mycolactone (step 3), and concentrated by means of a magnetic rack (step 4). The supernatant would be removed (step 5) and the magnetic nanoshells resuspended in chase buffer (step 6) before being added to the lateral flow assay (step 7).



```
138
```

```
139
```

Figure 4. Assay workflow, as initially envisioned.

Monoclonal antibodies. The generation of mouse monoclonal antibodies to mycolactone has been previously described [17]. The clone chosen for this application was JD5.1, produced by Swiss TPH (Basel, Switzerland) purified from hybridoma culture supernatants by affinity chromatography using a HiTrap Protein A HP column (Cytiva). Two other anti-mycolactone clones were deprioritized: JD5.11 which gave problems with reproducibility, and clone LW2.2 which appeared to have slower binding kinetics.

Conjugate. Magnetic gold nanoshells were conjugated to mouse monoclonal antibody JD5.1 using
 EDC/sulfo-NHS chemistry. The magnetic nanoshells conjugated to JD5.1 will be referred to below as "the
 conjugate".

Lyophilization of the conjugate (optional). The conjugate was stored at 4 °C, and either used as such in solution, or later in the development cycle, in order to match the workflow of **Figure 4**, was freeze-dried as 3% solution in lyophilization medium (5% sucrose, 5% trehalose, 0.1% surfactant 10G in deionized water).

Mycolactone and mycolactone analogs. Synthetic mycolactone A/B, biotinylated analog PG-204, and acetyl analog PG-119 were prepared by the group of Prof. Altmann, ETH-Z, and stored frozen at –20 °C in DMSO [20, 21]. Mycolactone sourced from WHO in ethyl acetate gave inferior results for reasons that were not investigated and was not further used (data not shown).

Test strips. The test strips were built using a glass fiber pad (Ahlstrom grade 8951), nitrocellulose type
CNPF-SN12, 10 μM (MDI, Advanced Microdevices PVT. LTD) and an absorbent pad (Ahlstrom, grade 222)
affixed to a 300 x 60 mm backing card (Lohmann LC-58803) with 2 mm overlaps. The strips were 4 x 60
mm, placed in an off-the-shelf cassette.

160 Extraction buffer. Mycolactone was extracted from simulated or real samples using an extraction buffer 161 made of 100 mM triethanolamine (TEA). When testing contrived samples, the pH was adjusted to 7.8. 162 Upon re-optimization with clinical samples, the optimal pH was found to be 10.4. For evaluation of clinical 163 samples, addition of a Heterophilic Blocking Reagent (HBR) was found to be necessary to eliminate matrix 164 effects. For these samples, a heterophilic blocking tube (Scantibodies, cat# PN 3IX762) was reconstituted 165 with 0.5 mL of extraction buffer and used in optimized amounts for each lot of conjugate, at a final 166 concentration of 2–5%. The TEA buffer was stored in glass bottles at room temperature, and HBR was 167 prepared and stored in 1.5 mL Axygen vials (Axygen, cat# MCT-150-L-C) at 4°C.

168 Chase buffer. The chase buffer was prepared with 2% proprietary detergent, 0.1% proprietary surfactant,
169 0.1% casein (Sigma, cat# G7078-500G) prepared by incubation in sodium tetraborate decahydrate pH 8.5
170 at 37 °C for 24 hours, and 0.05% Proclin (Sigma, cat# 48912-U) in PBS. The pH was adjusted with sodium
171 hydroxide to pH 8.9 for experiments with clinical samples.

172 Simulated wound exudate and other test materials. Based on a published biochemical analysis of wound 173 fluids from leg ulcers [22], we concluded that wound fluid could be approximated by mixing equal volumes 174 of negative human serum (NHS, ConeBio, cat# 4090) and PBS (FisherScientific, cat# 28372). We called this 175 1:1 mixture of NHS:PBS Simulated Wound Exudate (SWE). Positive simulated samples were prepared by 176 spiking SWE with synthetic mycolactone A/B prepared from a mycolactone stock solution (1 mg/mL in 177 DMSO) diluted in ethanol by a factor of 135 to reach a 10 μ M concentration. Positive controls were 178 prepared each containing 7 ng of mycolactone per sample, by diluting 1 μ L of 10 μ M mycolactone in 179 ethanol to a final volume of 75 μ L with SWE (for testing without a swab) or by diluting 1 μ L of 10 μ M 180 mycolactone in ethanol to a final volume of 50 μ L with SWE (for testing with a swab). Sterile swabs with 181 a flock-tipped applicator and polystyrene handle (Copan, Cat #25-3306-H BT) were used for testing with 182 swabs.

Clinical wound exudates. Wound swab extracts from cases that were initially suspected to be Buruli ulcer but later found to be PCR-negative (**Figure 8**) were kindly provided by Dr. Anthony Ablordey from the Noguchi Memorial Institute for Medical Research, University of Ghana. Those extracts were received already extracted in water instead of TEA. Additional samples were collected from suspected Buruli ulcer lesions but that proved negative for mycolactone with our rapid test were provided by The Pasteur Center in Cameroon, Yaoundé, Cameroon, Pasteur Institute Côte d'Ivoire, Abidjan, Côte d'Ivoire, and Hope Commission International, Abidjan, Côte d'Ivoire.

190 Clinical samples from Ghana were taken at the hospital or health centres as part of the routine diagnostic 191 procedure and case confirmation recommended by WHO and sent to the Noguchi Memorial Institute for 192 Medical Research (NMIMR) for analysis. Ethical approval for collection and use of patients' samples was 193 obtained from the Institutional Review Board of the Noguchi Memorial Institute for Medical Research 194 (NMIMR; Study number: NMIMR-IRB CPN 024/18–19). Patients were required to sign an informed 195 consent. To ensure anonymity, personal information such as names, and other personal identifiers associated with patient's samples were replaced with codes. Similarly, Clinical Samples from Ivory Coast 196 197 and Cameroon were collected under IRB approved protocols for the sake of this study and with informed 198 consent. The protocols were cleared by the Comité National d'Ethique des Sciences de la Vie et de la Santé, 199 Ministère de la Santé, Côte d'Ivoire, 2021, IRB 000111917 and the Comité National d'Ethique de La 200 Recherche pour la Santé Humaine, Ministère de la Santé, Cameroun, IRB 2021/06/1367.

201 **Mycobacteria cultures.** *Mycobacterium marinum* and *Mycobacterium ulcerans* were cultured as 202 previously described [23].

203 Procedure to run the assay using a simulated sample and no swabs (Figure 4 Steps, 2-7). For the sake of 204 simplicity, most of the assay development work was carried out without a swab, skipping steps 0 and 1 of 205 Figure 4. Instead, 75 µL of negative SWE or positive (mycolactone spiked) SWE were placed in a 1.5 mL 206 Axygen vial (Axygen, cat# MCT-150-NC) and diluted with 0.5 mL of extraction buffer. Then $1-2 \mu L$ of 207 conjugate Mag-GNS-JD5.1 in solution (OD= 20, or an equivalent of the reconstituted lyophilized conjugate) 208 was added to the extract, vortexed briefly, and incubated for 30 min, then placed on a magnetic rack to 209 concentrate the nanoparticles for 30 min. During incubations the vials were protected from the light to 210 avoid mycolactone degradation. The conjugate was concentrated with a neodymium magnet (Poichekailov 211 magnetic racks, US, [24]), the supernatant was removed and the particles resuspended in 2 drops 212 (approximately 60 μ L) of chase buffer and transferred to the test sample port. The test developed for 30

213 min prior to imaging and quantitation with a benchtop reader (Leelu v3.0, Lumos Diagnostics, Carlsbad,214 CA).

Procedure to run the assay using a simulated sample absorbed onto a swab (Figure 4, Steps 1-7). To simulate a clinical specimen absorbed on a swab, a swab (Copan, 25-3306-H BT) was placed in an Axygen vial containing 50 μL of positive or negative SWE until all the liquid was absorbed. Next, the swab was placed in a fresh 1.5 mL Axygen vial and extracted with 0.5 mL of extraction buffer. The swab was rotated 3–5 times in the extraction buffer while pressing against the sides of the vial, left in the vial for 5 min, and pressed against the wall while rotating and lifting to recover as much liquid as possible. The swab was discarded, and the next steps (steps 2–7) were conducted with the extract as described in the previous

222 paragraph for SWE.

Procedure to run the assay with clinical wound exudates (with HBR, pH 10.4 buffer). The retrospective PCR negative clinical wound swabs from Ghana had been extracted in water prior to receipt. These samples were tested with two methods (1) as received, following the protocol for simulated extracts and (2) by first adding 10x concentrated TEA extraction buffer to final x1 concentration to improve conjugate collection on a magnet. A heterophilic blocking reagent (HBR) was added to clinical wound extracts at 2– 5% concentration to prevent possible interference of the conjugate with heterophilic antibodies or other matrix effects, then samples were tested the same as described for the simulated extract.

Quantification. Test line intensities were quantified with a benchtop reader (Leelu v3.0, Lumos
 Diagnostics, Carlsbad). We investigated both the test line intensity alone, as well as the ratio between test
 and control line (T/C) with the latter giving the most reproducible results.

Statistical Analysis. P-values were calculated using GraphPad Prism, version 10, assuming Gaussian
 distributions, and not assuming equal standard deviations (Welch's correction).

235 Results

Optimal conditions. As described under Materials and Methods, based on limited literature [12] our initial estimate was that clinically relevant concentrations of mycolactone would be 15–150 ng/swab. Opting for a conservative approach, we aimed at developing a test that could detect half of the lowest amount that we were expecting to find in swabs (*i.e.*, approximately 7.5 ng of mycolactone). To standardize the testing method and to overcome the paucity of clinical materials, we prepared contrived samples in which wound exudate was simulated by using a 1:1 mixture of negative human serum and PBS. The simulated exudate was then spiked with known amounts of synthetic mycolactone A/B.

Assay optimization was extensive and is not described herein. Optimization was first performed with simulated wound exudates, without employing a swab. With this initial set of optimized conditions, the contrived sample (50–75 μ L) was diluted in extraction buffer (0.5 mL, pH 7.8), and incubated with the magnetic conjugate (1–2 μ L, OD 20) for 30 minutes. The magnetic conjugate was then recovered by placing it on a magnetic rack for 30 minutes, removing the supernatant, and adding 2 drops (approximately 60 μ L) of chase buffer (pH = 7.4). The resuspended nanoparticles were then added to the sample port of the cassette, and the assay ran for 30 minutes before analysis.


250 These conditions worked well with contrived samples but as described below, failed when using clinical 251 samples. This triggered a second round of optimization, which led to increasing the pH of the extractions 252 and chase buffers while leaving the other parameters unchanged. Thus, when using clinical samples, we 253 employed a TEA extraction buffer adjusted to pH = 10.4 instead of pH = 7.8 (0.5 mL). The incubation with 254 the magnetic conjugate (1–2 µL, OD 20, 30 min) remained the same, and so did the magnetic conjugate 255 recovery method (magnetic rack, 30 min, and removing the supernatant). The newly optimized chase 256 buffer was adjusted to a pH = 8.9 instead of pH = 7.4 (2 drops). The rest of the procedure was not modified: 257 the resuspended nanoparticles were then added to the sample port of the cassette, after which the test

developed over 30 minutes. The fully optimized conditions can be found in the Instructions for Useincluded in the Supplementary Information.

260 Limit of detection with simulated wound exudate. Samples of mycolactone A/B serially diluted in ethanol 261 were added to the simulated wound exudates and processed according to the optimized conditions 262 described in the previous two paragraphs. At this stage of development, the extraction buffer had a pH = 263 7.8 and the chase buffer had a pH = 7.4. The intensity of the test and control lines were quantified with a 264 benchtop reader. The more mycolactone in the sample, the more it competes with PG-204 immobilized 265 at the test for binding the conjugate. Hence, the higher the mycolactone concentration, the lower the test 266 line intensity. When looking at the test with the unaided eye (Figure 5), the test line could be easily seen 267 if no mycolactone was present, and the test line became barely visible when 7 mg of mycolactone were 268 added to the simulated wound exudate. Similarly, when quantifying the intensity of the test lines with a 269 benchtop reader (Figure 6), the intensity decreased from approximately 0.08 reader units in the absence 270 of mycolactone to 0.02 units in the presence of 7 ng mycolactone, and the difference was statistically 271 significant (p=0.006). All samples contained the same amount of DMSO, indicating that the dose response 272 was due to mycolactone and was not an artifact due to DMSO.

273


274



276

277	Figure 5. Limit of detection of the rapid test using simulated samples spiked
278	with synthetic mycolactone (n=3). Visually, a difference can be seen between
279	no mycolactone and 7 ng of mycolactone, where the latter causes a nearly
280	complete inhibition of the test line.

281



282

Figure 6. Limit of detection of the rapid test using simulated samples spiked with synthetic mycolactone. When measured with a reader, the difference between no mycolactone and 7 ng of mycolactone is statistically significant (p < 0.05).

287 **Specificity with cell cultures of different mycobacteria strains.** Having developed a test that appeared to 288 have the desired analytical sensitivity, we next evaluated its specificity. This was done by comparing 289 supernatants from laboratory-grown cell cultures of M. ulcerans and M. marinum, a non-pathogenic 290 mycobacterium lacking the giant 174 kb symbiotic plasmid pMUM001 responsible for mycolactone 291 production in *M. ulcerans*. As shown in Figure 7, *M. ulcerans* supernatant, which contains mycolactone, 292 led to an inhibition of the test line, while *M. marinum* cell cultures, which do not contain mycolactone, did not inhibit the test line formation, demonstrating that our assay shows no cross-reactivity with M. 293 294 *marinum* samples.

295

Α

296

297	Figure 7. Cross-reactivity testing the assay with <i>M. ulcerans</i> vs <i>M. marinum</i>
298	supernatant. While M. ulcerans produces mycolactone leading to an inhibited
299	signal at the test line, M. marinum does not synthesize mycolactone and
300	therefore the test line remains visible.


301

302 **Test results with swabs and simulated wound exudates.** Having in hand a test that was analytically 303 sensitive and specific, we next investigated the use of a swab. The concern was that a swab would be

304 mandatory for sample collection but that mycolactone, being so lipophilic with a calculated logP of 9.0 305 [25], may stick to the fibers of which the swab is made, and not be easily extracted into an aqueous 306 solution. To investigate this matter, an aliquot of 50 µL SWE was deposited on a swab and then extracted 307 with the extraction buffer for 5–10 min. As reference, the same SWE was directly diluted with extraction 308 buffer, without using a swab. The tests showed a nearly identical behavior when directly diluting the SWE 309 in extraction buffer (not using a swab) versus first absorbing the SWE onto a swab and then extracting it 310 (Figure 8A). Based on the quantification of the test line intensities, we calculated that 80% of the 311 mycolactone was recovered from the swab, and the remaining 20% were left within the extract trapped in the swab fibers. Additionally, the swabs containing simulated samples could be stored for at least 48 hours 312 313 at 4 °C before extraction without noticeable degradation of mycolactone (Figure 8B). This feature is useful 314 for shipping samples from the field to a local laboratory.

Α.





316	Figure 8. A. Effect of swab on test results and sample stability when absorbed
317	on a swab. Panel A. The test results are not impacted if simulated wound exudate
318	is pre-absorbed on a swab. Panel B. Once absorbed on a swab, simulated wound
319	exudates are stable for at least 48 hours at 4 °C.

Optimizing the test conditions to real wound exudates. Having established the performance of the test with simulated wound exudates, we moved to real wound exudates, collected from ulcers in Buruli ulcerendemic areas (Ghana). Contrary to simulated wound exudates, real clinical wound exudates collected in the field represented a challenging matrix that varied from patient-to-patient and included blood and various other debris (**Figure 9**).

325




326

327

Figure 9. Aspect of 6 different wound exudate extracts as received from Ghana.


To our surprise, both the test and control line frequently disappeared, even though the samples had tested negative for Buruli Ulcer by PCR. Some clinical samples contained debris and particulates, sometimes in large amounts and possibly deriving from herbal medications and necrotic tissues. These debris interfered with the test, although could not explain alone all the cases where test and control lines disappeared.

Several parameters were optimized to achieve 100% validity (*i.e.,* control line always visible) with clinical swabs. First, we reasoned that the test employs mouse monoclonal antibodies, and that heterophilic antibodies present in the wound exudates may have a deleterious impact, especially when using endemic samples from populations often exposed to rodents. This risk was mitigated by adding Heterophilic-Blocking Reagents (HBR) which led to a significant improvement of the line intensities (**Figure 10**).



Second, we removed the particulate material from the swab extracts by centrifugation. This can be done easily in the laboratory but not in the field. Alternatively, doubling the amount of buffer with which the mycolactone is extracted from the swab (1.0 mL instead of 0.5 mL) lowered the impact of particulate on magnetic nanoparticle recovery (data not shown). Third, increasing the pH of both the extraction buffer (from 7.8 to 10.4) and chase buffer (from 7.4 to 8.9) increased the intensity of both the control and test lines (**Figure 11**). Taken together, these modifications provided 100% validity, as judged by the presence of a visible control line in all of the 207 clinical swabs analyzed.

349




351

Figure 11. Increasing the pH of the extraction buffer from 7.9 to 10 leads to stronger control lines (left panel) and test line intensity (right panel) when testing simulated wound exudate samples, either not spiked with mycolactone (negative; -ve) or spiked with 7 ng mycolactone (positive; +ve).

356

357 Calibration curve and limit of detection (LOD) with real wound exudates. After optimizations (sample 358 centrifugation, addition of HBR and pH optimization of extraction and chase buffers) were introduced we 359 re-examined the dose-response curve using real exudates extracted with TEA pH 10.4. Wound extracts 360 from LFA-negative lesions were pooled, and then spiked with synthetic mycolactone. Rather than reporting 361 the absolute intensity of the test line as we did in the original LOD testing (Figures 5, 6), the test to control 362 (T/C) line ratios were calculated, leading to more consistent results (Figure 12). In the absence of mycolactone, the T/C ratio was around 0.9. The presence of 3.7 ng of mycolactone/sample gave a T/C ratio 363 364 in the 0.42–0.44 range that was easily distinguished from the T/C ratio obtained without mycolactone. 365 Hence, under fully optimized conditions, the LOD was around 3.7 ng of mycolactone using extracts from 366 clinical samples as the sample matrix.





370Figure 12. Mycolactone dose response in pooled Buruli ulcer negative swab371extracts from Cameroon spiked with synthetic mycolactone A/B. T/C – test-to-372control line ratio quantified with Lumos Leelu benchtop reader.

373

Additional work. Additional work that is not described herein included the freeze-drying of the conjugate, and the demonstration that once lyophilized the conjugate is stable for at least 2 weeks at 40°C, allowing for it to be shipped to disease endemic countries and field settings without prohibitive cold-chain requirements. We also demonstrated that a positive control could be made with mycolactone analog PG-119 (Figure 1). Analog PG-119, which lacks the side-chain of mycolactone, is also detected by monoclonal antibody JD5.1, with the same or better sensitivity as mycolactone A/B. This offers two major advantages, as PG-119 is easier to synthesize and is not photosensitive.

381 Discussion

Target product profile. Based on the WHO target product profile (TPP) for Buruli ulcer, we developed a rapid diagnostic tests (RDT) targeting mycolactone. While the TPP specifies mycolactone as the analyte of choice, it does not specify the required limit of detection. Based on very limited literature data [12, 26], we inferred that a test capable of detecting 15 ng of mycolactone would provide the required clinical sensitivity. To be conservative, we defined that the limit of detection (LOD) should be 7 ng of mycolactone per sample or lower. It remains to be seen if this truly translates to proper clinical sensitivity [27].

388 Developing a mycolactone-based test was difficult for several reasons. Firstly, the matrix in which 389 mycolactone is found is complex. The disease starts as a papule, that turns into a nodule, and eventually 390 into a large open wound (ulcer). Nodules can be sampled by means of fine needle aspirates, while wounds 391 are sampled with swabs. Since people are more likely to seek treatment after the appearance of an ulcer, 392 we elected to detect mycolactone in wound exudates collected with swabs. Wound exudates are an 393 unusual matrix for lateral flow assay development, as they vary in physical appearance and composition 394 from one person to another – for instance some lesions can be relatively dry and others exudative. Another 395 limitation of wound exudates is that they are available only in small amounts, unlike more mainstream 396 matrices such as plasma or urine. Furthermore, the amount of mycolactone in wound exudates can only 397 be limited, in part because *M. ulcerans* replicates slowly, therefore generating only low concentrations of 398 mycolactone, and because mycolactone is photodegradable [28] and hence can be cleared from the 399 wound. Another complication is that it is not always clear if patients have applied herbal medications or 400 other topical treatments to the ulcer and how that may affect the viability of *M. ulcerans* and its ability to 401 produce mycolactone, and if those treatments have potential to interfere with the test. Finally, 402 mycolactone is a highly hydrophobic molecule (cLogP = 9.0) [29, 30], and therefore has low affinity for 403 aqueous mediums and can stick to laboratory plasticware.

404 The developed Buruli ulcer RDT was configured as a competitive assay to detect mycolactone using novel 405 magnetic gold nanoshells, mycolactone-specific monoclonal antibodies [17] and a biotinylated probe. 406 Unlike normal RDTs, a mycolactone concentration step was required. This was accomplished by leveraging 407 the magnetic properties of the nanoparticles, allowing the assay to be performed in under two hours, with 408 minimal equipment (Figure 1). We initially noticed a strong difference between simulated wound exudate, 409 prepared by mixing equal volumes of negative human serum and PBS, which gives clean test results, and 410 real wound exudates which gave in some cases invalid tests, with no test line and no control line. In these 411 problematic cases, the nanoparticles seemed to be especially difficult to recover magnetically. This 412 behavior was tentatively ascribed to the presence of heterophilic antibodies recognizing the mouse anti-413 mycolactone antibody, and either modifying the charge of the surface of the gold nanoparticle or causing 414 the nanoparticles to cross-link with each other and complicating their recovery. Regardless of whether this 415 rationale is correct or not, the unwanted absence of control line could be corrected by adding HBR to the 416 extraction buffer and by using higher pH in the extraction and chase buffers. The addition of HBR added 417 an extra step to the workflow presented in Figure 1, and the final workflow can be found in Supplementary 418 Information section (Figure S1 and Instructions for Use).

The limit of detection of the assay was 3.7–7 ng mycolactone per sample analyzed, and this was estimated to be sufficient for the test to be clinically relevant. We verified that the magnetic nanoparticles could be freeze-dried and be stable in this format at 40 °C for at least 2 weeks for shipping purposes. We also verified that mycolactone is stable for at least 2 days at 4 °C once absorbed on a swab, enabling the samples to be transported from the field to a district laboratory. The materials (swabs, vials) selected in this publication were compatible with mycolactone and allowed for maximum recovery.

In conclusion, a prototype RDT was developed that met the WHO TPP specification of detecting
 mycolactone as the biomarker, and that met the self-imposed requirement of detecting at least 7 ng of

427 mycolactone in wound exudate. The test also met most of the WHO TPP parameters in that it was stable 428 for transportation at ambient temperature, and that a stable positive control was developed. Detailed 429 instructions for use were compiled and are available in the Supplementary Information. Based on this data, 430 the prototype was deemed worthy of advancing to field evaluations, with fresh clinical samples. These 431 results will be reported elsewhere.

432 Supporting Information

- Instructions for Use (pdf)
- Finalized workflow (Figure S1)
- Aspect of nanoparticles on the rack (Figure S2)

436 Acknowledgements

This work received financial support from FIND through funding from Medicor Foundation, UBS Optimus
Foundation, Swiss Agency for Development and Cooperation (SDC), KfW-BMBF and Global Health
Innovative Technology (GHIT) Fund. The funders played no role in the decision to publish.

The authors thank all those involved in sample collection and field testing of the device, including Dr. Sara Eyangoh, Mr. Hycenth Numfor, and Ms. Valerie Donkeng Donfack and the team from Buruli Ulcer Laboratory Network (BU-LABNET), Centre Pasteur du Cameroun, Dr. Aka N'guetta and Dr. David Coulibaly from the Institute Pasteur de Côte d'Ivoire, Mr. Aubin Yao from the Hope Commission International, Côte d'Ivoire and the team from the National Buruli Ulcer Control Program of Côte d'Ivoire. And Dr. A. Ablordey and his team at the Noguchi Memorial Institute for Medical Research.

446 References

Guarner J. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease. J Clin Microbiol.
 2018;56(4). Epub 20180326. doi: 10.1128/JCM.01507-17. PubMed PMID: 29343539; PubMed Central
 PMCID: PMCPMC5869816.

Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, et al. Buruli Ulcer: a
 Review of the Current Knowledge. Curr Trop Med Rep. 2018;5(4):247-56. Epub 20180928. doi:
 10.1007/s40475-018-0166-2. PubMed PMID: 30460172; PubMed Central PMCID: PMCPMC6223704.

Omansen TF, Erbowor-Becksen A, Yotsu R, van der Werf TS, Tiendrebeogo A, Grout L, et al. Global
 Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets. Emerg Infect
 Dis. 2019;25(12):2183-90. doi: 10.3201/eid2512.190427. PubMed PMID: 31742506; PubMed Central
 PMCID: PMCPMC6874257.

Bartley B, O'Brien D. Buruli ulcer - A neglected tropical disease in the Barwon region of Victoria,
 Australia: An emerging public health threat with local and national ramifications. Emerg Med Australas.
 2023;35(4):697-701. Epub 20230504. doi: 10.1111/1742-6723.14235. PubMed PMID: 37454363.

Vandelannoote K, Buultjens AH, Porter JL, Velink A, Wallace JR, Blasdell KR, et al. Statistical
modeling based on structured surveys of Australian native possum excreta harboring Mycobacterium
ulcerans predicts Buruli ulcer occurrence in humans. Elife. 2023;12. Epub 20230414. doi:
10.7554/eLife.84983. PubMed PMID: 37057888; PubMed Central PMCID: PMCPMC10154024.

Muleta AJ, Lappan R, Stinear TP, Greening C. Understanding the transmission of Mycobacterium
 ulcerans: A step towards controlling Buruli ulcer. PLoS Negl Trop Dis. 2021;15(8):e0009678. Epub
 20210826. doi: 10.1371/journal.pntd.0009678. PubMed PMID: 34437549; PubMed Central PMCID:
 PMCPMC8389476.

7. 468 WHO. Number of New Reported Cases of Buruli Ulcer. Available from: 469 https://www.who.int/data/gho/data/indicators/indicator-details/GHO/number-of-new-reported-cases-470 of-buruli-ulcer. 471 8. Timothy JWS, Pullan RL, Yotsu RR. Methods and Approaches for Buruli Ulcer Surveillance in Africa: 472 Lessons Learnt and Future Directions. Methods Mol Biol. 2022;2387:87-102. doi: 10.1007/978-1-0716-473 1779-3 10. PubMed PMID: 34643905.

O'Brien DP, Friedman ND, Walton A, Hughes A, Athan E. Risk Factors Associated with Antibiotic
 Treatment Failure of Buruli Ulcer. Antimicrob Agents Chemother. 2020;64(9). Epub 20200820. doi:
 10.1128/AAC.00722-20. PubMed PMID: 32571813; PubMed Central PMCID: PMCPMC7449191.

Beissner M, Phillips RO, Battke F, Bauer M, Badziklou K, Sarfo FS, et al. Loop-Mediated Isothermal
Amplification for Laboratory Confirmation of Buruli Ulcer Disease-Towards a Point-of-Care Test. PLoS Negl
Trop Dis. 2015;9(11):e0004219. Epub 20151113. doi: 10.1371/journal.pntd.0004219. PubMed PMID:
26566026; PubMed Central PMCID: PMCPMC4643924.

481 11. Frimpong M, Frimpong VNB, Numfor H, Donkeng Donfack V, Amedior JS, Deegbe DE, et al. Multi-482 centric evaluation of Biomeme Franklin Mobile qPCR for rapid detection of Mycobacterium ulcerans in 483 Negl Trop clinical specimens. PLoS Dis. 2023;17(5):e0011373. Epub 20230525. doi: 484 10.1371/journal.pntd.0011373. PubMed PMID: 37228126; PubMed Central PMCID: PMCPMC10246808.

Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, et al. Mycolactone diffuses into
the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring. PLoS Negl
Trop Dis. 2011;5(7):e1237. Epub 20110719. doi: 10.1371/journal.pntd.0001237. PubMed PMID:
21811642; PubMed Central PMCID: PMCPMC3139662.

Akolgo GA, Partridge BM, T DC, Amewu RK. Alternative boronic acids in the detection of
Mycolactone A/B using the thin layer chromatography (f-TLC) method for diagnosis of Buruli ulcer. BMC

- 491 Infect Dis. 2023;23(1):495. Epub 20230727. doi: 10.1186/s12879-023-08426-2. PubMed PMID: 37501134;
- 492 PubMed Central PMCID: PMCPMC10373253.
- 493 14. FIND. Report of a WHO–FIND meeting on diagnostics for Buruli ulcer2018. Available from:
- 494 https://www.finddx.org/wp-
- 495 content/uploads/2022/12/20180901 tpp ntds buruli who cds FV EN.pdf.
- 496 15. WHO. Target product profile for a rapid test for diagnosis of Buruli ulcer at the primary health-care
- 497 level2022. Available from: https://iris.who.int/bitstream/handle/10665/353982/9789240043251-
- 498 <u>eng.pdf?sequence=1</u>.
- 499 16. Hall B, Simmonds R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor
- 500 mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans.
- 501 2014;42(1):177-83. doi: 10.1042/BST20130133. PubMed PMID: 24450648.
- 502 17. Dangy JP, Scherr N, Gersbach P, Hug MN, Bieri R, Bomio C, et al. Antibody-Mediated Neutralization
- 503 of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans. PLoS Negl
- 504 Trop Dis. 2016;10(6):e0004808. Epub 20160628. doi: 10.1371/journal.pntd.0004808. PubMed PMID:
- 505 27351976; PubMed Central PMCID: PMCPMC4924874.
- Warryn L, Dangy JP, Gersbach P, Gehringer M, Schafer A, Ruf MT, et al. Development of an ELISA
 for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. PLoS Negl
 Trop Dis. 2020;14(6):e0008357. Epub 20200626. doi: 10.1371/journal.pntd.0008357. PubMed PMID:
 32589646; PubMed Central PMCID: PMCPMC7347236.
- Warryn L, Dangy JP, Gersbach P, Gehringer M, Altmann KH, Pluschke G. An Antigen Capture Assay
 for the Detection of Mycolactone, the Polyketide Toxin of Mycobacterium ulcerans. J Immunol.
 2021;206(11):2753-62. Epub 20210524. doi: 10.4049/jimmunol.2001232. PubMed PMID: 34031146;
 PubMed Central PMCID: PMCPMC8176938.

514 Gehringer M, Mader P, Gersbach P, Pfeiffer B, Scherr N, Dangy JP, et al. Configurationally Stabilized 20. 515 Analogs of M. ulcerans Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry 516 for Mycolactone Virulence. Org Lett. 2019;21(15):5853-7. Epub 20190711. doi: 517 10.1021/acs.orglett.9b01947. PubMed PMID: 31295000.

Scherr N, Gersbach P, Dangy JP, Bomio C, Li J, Altmann KH, et al. Structure-activity relationship
studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans. PLoS Negl Trop Dis.
2013;7(3):e2143. Epub 20130328. doi: 10.1371/journal.pntd.0002143. PubMed PMID: 23556027;
PubMed Central PMCID: PMCPMC3610637.

Trengove NJ, Langton SR, Stacey MC. Biochemical analysis of wound fluid from nonhealing and
healing chronic leg ulcers. Wound Repair Regen. 1996;4(2):234-9. doi: 10.1046/j.1524-475X.1996.40211.x.
PubMed PMID: 17177819.

Porter JL, Tobias NJ, Hong H, Tuck KL, Jenkin GA, Stinear TP. Transfer, stable maintenance and
expression of the mycolactone polyketide megasynthase mls genes in a recombination-impaired
Mycobacterium marinum. Microbiology (Reading). 2009;155(Pt 6):1923-33. Epub 20090421. doi:
10.1099/mic.0.027029-0. PubMed PMID: 19383681.

529 24. Magnetic rack separators. Available from: <u>https://www.ebay.com/usr/pochekailov</u>.

López CA, Unkefer CJ, Swanson BI, Swanson JMJ, Gnanakaran S. Membrane perturbing properties
of toxin mycolactone from Mycobacterium ulcerans. PLoS Comput Biol. 2018;14(2):e1005972. Epub
20180205. doi: 10.1371/journal.pcbi.1005972. PubMed PMID: 29401455; PubMed Central PMCID:
PMCPMC5814095.

Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, et al. Detection of Mycolactone A/B
in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis. 2010;4(1):e577. Epub 20100105.
doi: 10.1371/journal.pntd.0000577. PubMed PMID: 20052267; PubMed Central PMCID:
PMCPMC2791843.

538 27. 2011 Sea. In the literature report, 1 mL extracts were concentrated to 0.5 mL, and analyzed by 539 HPLC/MS/MS. After this twofold concentration step, mycolactone was present in the 30–300 ng/mL range 540 (40-400 nM) in 20/23 samples, and undetectable in the remaining three. Hence before evaporation, 541 mycolactone concentration was 15–150 ng/mL range (20–200 nM), and the absolute mycolactone content 542 was 15–150 ng/samples in 20/23 (87%) of the patients. 543 28. Marion E, Prado S, Cano C, Babonneau J, Ghamrawi S, Marsollier L. Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storage. PLoS One. 544 545 2012;7(4):e33600. Epub 20120413. doi: 10.1371/journal.pone.0033600. PubMed PMID: 22514607; PubMed Central PMCID: PMCPMC3326021. 546 547 29. Nitenberg M, Benarouche A, Maniti O, Marion E, Marsollier L, Gean J, et al. The potent effect of mycolactone on lipid membranes. PLoS Pathog. 2018;14(1):e1006814. Epub 20180110. doi: 548

549 10.1371/journal.ppat.1006814. PubMed PMID: 29320578; PubMed Central PMCID: PMCPMC5779694.

30. Kubicek-Sutherland JZ, Vu DM, Anderson AS, Sanchez TC, Converse PJ, Marti-Arbona R, et al.
Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of
Amphiphilic Mycolactone. Toxins (Basel). 2019;11(4). Epub 20190404. doi: 10.3390/toxins11040202.
PubMed PMID: 30987300; PubMed Central PMCID: PMCPMC6520765.